🔗 Visit the ClinicalTrials.gov page for NCT02024087
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N. | Gynecol Oncol | 2015 | 0.92 |
| 2 | Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. | World J Gastroenterol | 2015 | 0.87 |